眼底抗血管内皮生长因子药物应用与创新  

An update on anti-vascular endothelial growth factor therapy in retinal diseases

作　　者：鄢闻嘉 罗德伦 冯加劲 丁小燕[1] Yan Wenjia;Luo Delun;Feng Jiajin;Ding Xiaoyan(Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangzhou 510000,China;Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;Chengdu Jingrunze Biotechnologies,LTD,Chengdu 610095,China)

机构地区：[1]中山大学中山眼科中心,广州510060 [2]成都中医药大学中医药创新研究院,成都611137 [3]成都景润泽基因科技有限公司,成都610095

出　　处：《中华眼底病杂志》2023年第8期701-707,共7页Chinese Journal of Ocular Fundus Diseases

基　　金：广东省高水平医院建设项目(303020107,303010303058);国家自然科学基金(82271092);广东省基础与应用基础研究基金(2023A1515010430)。

摘　　要：血管内皮生长因子(VEGF)是一类能促进血管生成,增加血管通透性的多功能因子,其异常增高在渗出型老年性黄斑变性、糖尿病黄斑水肿等常见视网膜疾患中起到关键作用。抗VEGF药物治疗可抑制血管生成、减轻血管渗漏和水肿,从而延缓疾病进展,稳定或提高视力。目前抗VEGF药物临床应用已取得了满意疗效,但也存在注射频率高、患者负担重、潜在全身副作用、药物不应答等问题。针对这些局限,当前主要的研发方向包括生物仿制药、多靶点药物、药物缓释系统、口服抗VEGF药物和基因治疗等。部分药物已展现出较大的潜力,有望为眼科抗VEGF药物治疗开启新篇章。Vascular endothelial growth factor(VEGF)is a multifunctional factor that promotes blood vessel formation and increases vascular permeability.Its abnormal elevation plays a key role in common retinal diseases such as wet age-related macular degeneration and diabetic macular edema.Anti-VEGF therapy can inhibit angiogenesis,reduce vascular leakage and edema,thereby delaying disease progression and stabilizing or improving vision.Currently,the clinical application of anti-VEGF drugs has achieved satisfactory therapeutic effects,but there are also issues such as high injection frequency,heavy economy burden,potential systemic side effects,and non-responsiveness.To address these issues,current research and development mainly aim on biosimilars,multi-target drugs,drug delivery systems,oral anti-VEGF drugs,and gene therapy.Some drugs have shown great potential and are expected to turn over a new leaf for anti-VEGF treatment in ophthalmology.

关 键 词：血管内皮生长因子 抗血管内皮生长因子药物 老年性黄斑变性 基因治疗 综述 

分 类 号：R774[医药卫生—眼科]